Lista de obras -

A bipartite structural organization defines the SERINC family of HIV-1 restriction factors

artículo científico publicado en 2020

A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants

artículo científico publicado en 2008

Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26

artículo científico publicado en 2020

Correction: The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles

scientific article published on 01 December 2019

Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions

artículo científico publicado en 2010

Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers ⬇️

artículo científico publicado el 30 de enero de 1998

Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef.

artículo científico publicado en 2007

Galanin pathogenic mutations in temporal lobe epilepsy

artículo científico publicado en 2015

HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation

artículo científico publicado en 2015

Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection

artículo científico publicado en 2002

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research

artículo científico publicado en 2008

Identifying features of the lentiviral genome crucial for the establishment of latency

Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals

scientific article published on 10 November 2020

Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity

artículo científico publicado en 2019

Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5.

artículo científico publicado en 2017

Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration

artículo científico publicado en 2015

Lv4, an activity that restricts nuclear entry of SIVMAC/SIVSM in human blood cells

artículo científico publicado en 2013

MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.

artículo científico publicado en 2010

Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75.

artículo científico publicado en 2003

Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles

artículo científico publicado en 2008

Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

artículo científico publicado en 2011

Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix

artículo científico publicado en 2002

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol

artículo científico publicado en 2021

Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors

artículo científico publicado en 2012

Retroviral factors promoting infectivity

artículo científico publicado en 2014

S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

artículo científico publicado en 2016

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

artículo científico publicado en 2021

SERINC5 as a New Restriction Factor for Human Immunodeficiency Virus and Murine Leukemia Virus

artículo científico publicado en 2018

SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

artículo científico publicado en 2017

Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve

artículo científico publicado en 2021

TRIM5 is an innate immune sensor for the retrovirus capsid lattice

artículo científico publicado en 2011

The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor

artículo científico publicado en 2016

The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild

artículo científico publicado en 2016

The activity of Nef on HIV-1 infectivity

artículo científico publicado en 2014

The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists

artículo científico publicado en 2018

The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.

artículo científico publicado en 2012

The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles

artículo científico publicado en 2017

Understanding the nature of the Nef requirement for HIV-1 infectivity

article published in 2013

Lista de obras de

A bipartite structural organization defines the SERINC family of HIV-1 restriction factors

A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants

Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26

Correction: The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles

Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions

Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers ⬇️

Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef.

Galanin pathogenic mutations in temporal lobe epilepsy

HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation

Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research

Identifying features of the lentiviral genome crucial for the establishment of latency

Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals

Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity

Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5.

Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration

Lv4, an activity that restricts nuclear entry of SIVMAC/SIVSM in human blood cells

MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.

Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75.

Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles

Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix

Proceedings of the Frontiers of Retrovirology Conference 2016.

Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol

Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors

Retroviral factors promoting infectivity

S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

SERINC5 as a New Restriction Factor for Human Immunodeficiency Virus and Murine Leukemia Virus

SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve

TRIM5 is an innate immune sensor for the retrovirus capsid lattice

The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor

The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild

The activity of Nef on HIV-1 infectivity

The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists

The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.

The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles

Understanding the nature of the Nef requirement for HIV-1 infectivity